🟢 ADMA Biologics is trading 25% up after raising full-year adjusted earnings outlook

ADMA Biologics is trading at $13.09 (+24.90%) on November 5 after reporting third-quarter results and raising its full-year adjusted earnings outlook.

• Revenue was $141.1 million; ASCENIV revenue rose 31% year over year to $124.7 million, and gross margin expanded to 71%.
• Management raised minimum adjusted net income guidance to $180 million and adjusted EBITDA guidance to $275 million, while maintaining revenue guidance of at least $530 million.
• A gain in the biotech sector also supported the move.